Join us on December 11, 2024, for a webinar discussing the latest research progress in cell therapy, with a focus on ongoing studies that examine both the benefits and limitations of expanding CAR-T therapy. This promising approach represents a pivotal shift toward more targeted and effective treatments, positioning CAR-T cell therapy as a powerful tool in the fight against cancer and other diseases. ?? Register here: https://bit.ly/48PpLLE
关于我们
Cusabio, established in 2007, has evolved from a small lab to a renowned global partner for researchers over the past 17+ years. Specializing in cancer, cell biology, immunology, neuroscience, and epigenetics, we offer an extensive range of products, including 60,000+ validated antibodies, 12,000+ recombinant proteins, 660+ cytokines, and thousands of ELISA kits. Our commitment to quality is the foundation of our service to clients. We dedicate substantial resources to develop, validate, manage, and enhance the quality of our products. This commitment has helped us become a trusted partner for numerous researchers worldwide, as evidenced by over 22,000 published papers citing our products. In addition to quality, Cusabio stands out for: * Competitive pricing: We are a manufacturer with an effective cost control system. So you can also get great price from us. * Professional and fast technical support: We have a skilled and passionate customer service team. No matter what problems you’ve got, they will always be there at any time and find solutions for you. We got a slogan since Cusabio was built, "your good partner in biology research". And we are proud to have already become a preferred choice for many researchers globally.
- 网站
-
https://www.cusabio.com/
Cusabio Technology LLC的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Houston，Texas
- 类型
- 私人持股
- 创立
- 2007
- 领域
- ELISA、antibody、recombinant protein和 protein expression
地点
-
主要
获取路线
Ste 610-322
7505 Fannin St.
US，Texas，Houston，77054
Cusabio Technology LLC员工
动态
-
Pancreatic cancer is mainly divided into exocrine tumors (95%) and rare endocrine tumors. Early symptoms like vague abdominal pain and fatigue are often overlooked, highlighting the importance of early diagnosis. To support your research, CUSABIO offers a curated list of popular targets and related products for pancreatic cancer mechanism studies and drug development. ?? Learn more: https://bit.ly/3ZhdbkR
-
-
A study from Kanazawa University last year revealed a new role for osteopontin in HCV-related hepatocellular carcinoma. The study identified CD44 as a prevalent marker for cancer stem cells (CSCs) across multiple cancers, making it a key focus in cancer therapy research. This article integrates various studies and data to explore CD44 from the following perspectives: https://bit.ly/3O7COyv
-
With CUSABIO ELISA Kits for Food Safety & Drug Residues researchers and labs can reliably detect antibiotic residues like chloramphenicol and tetracyclines, supporting food safety and antibiotic resistance studies. Learn more about our residue detection tools ?? https://bit.ly/4ey27EH #EuropeanAntibioticAwarenessDay #AntibioticResidues #FoodSafety #CUSABIO
-
-
Lung cancer includes two main types: small-cell (SCLC, 15%) and non-small-cell (NSCLC, 85%). NSCLC, which includes squamous-cell carcinoma, adenocarcinoma, and large-cell carcinoma, is crucial for guiding treatments. Recent insights into molecular abnormalities have enabled personalized therapies. Here, we highlight key lung cancer targets from the NCG database. Learn more: https://bit.ly/3YI2mH2
-
-
?? In a study led by Dr. Kun Jiang and his team, researchers reveal how Bacteroides fragilis secretes BfUbb, a ubiquitin-like protein, to disrupt rivals by inactivating an essential enzyme (PPIase) in sensitive strains. Structural analysis shows that resistant strains avoid this effect through a key amino acid variation, giving encoding strains a competitive edge, as confirmed by lab and gut studies. ?? Read more: https://lnkd.in/gxGGztQY
-
-
In fact, adults with diabetes have a 2-4 times higher risk of CVD than those without. Common factors like obesity, hypertension, and dyslipidemia further increase this risk. We’ve compiled FAQs on diabetes and CVD—learn more: https://bit.ly/3Z5PdsJ
-
-
Diabetes mellitus (DM) is a clinical syndrome resulting from insufficient insulin secretion or impaired insulin function. It is primarily characterized by chronic hyperglycemia and is often associated with various cardiovascular diseases. Complications include microvascular damage (e.g., retinopathy and nephropathy), macrovascular disease (e.g., cardiovascular disease), and neurological disorders. As modernization and lifestyle changes accelerate, diabetes prevalence is rising worldwide, making its treatment a global challenge. Read more: https://bit.ly/4fNJxcm
-
-
B7-H3 (CD276) stands out in the B7 family for its dual role in both activating and inhibiting immune responses. Its impact on tumor immunity and potential as a target in immunotherapy make it a focal point of current research. Want to understand B7-H3’s structure, receptor dynamics, and therapeutic potential? Explore our latest insights into its role in immune regulation and cancer treatment. ?? Read more: https://bit.ly/4ekywye
Costimulatory/Coinhibitory: Is B7-H3 An Enemy or A Friend?
Cusabio Technology LLC，发布于领英
-
?? World Pneumonia Day: Understanding the Pathogens Behind Pneumonia Pneumonia remains a leading cause of illness and death, especially in children and older adults. Key pathogens like Streptococcus pneumoniae, influenza virus, coronaviruses, and respiratory syncytial virus (RSV) play major roles in pneumonia cases worldwide. ?? Discover our research tools for pneumonia studies here: https://bit.ly/4eppnEM #WorldPneumoniaDay #PneumoniaResearch #PathogenResearch #CUSABIO
-